Saturday 17 October 2026
Export CVRX’s income statement to Excel — free account
CVRx, Inc.
CVRX Healthcare Medical Devices
CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 7.02%, free cash flow fell 11.2% and total debt rose 18.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
1.30
0.09
−6.47%
Follow CVRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.23 | 4.22 | 3.27 | 3.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.44) | (20.50) | (18.98) | (21.75) | |
P/B ratio |
6.83 | 8.57 | 4.71 | 4.39 | |
Price to Tangible BV |
6.83 | 8.57 | 4.71 | 4.39 | |
EV/Sales |
2.18 | 4.04 | 2.87 | 3.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.30) | (6.04) | (4.04) | (4.65) | |
EV/FCF |
(3.25) | (5.95) | (3.98) | (4.59) | |
Quick Ratio |
6.65 | 8.58 | 6.49 | 8.32 | |
Current Ratio |
8.04 | 10.20 | 7.63 | 9.62 | |
Net Debt/EBITDA |
0.47 | 1.16 | 2.39 | 2.97 | |
Debt/Assets |
63.47% | 58.65% | 47.25% | 44.42% | |
Debt/Equity |
2.94 | 2.01 | 1.26 | 1.03 | |
Asset Turnover |
0.58 | 0.52 | 0.48 | 0.47 | |
Operating CF/Net income |
0.63 | 0.93 | 0.82 | 0.75 | |
Capex/Depreciation |
(0.38) | (0.42) | (0.28) | (1.16) | |
Interest Coverage |
(8.25) | (7.84) | (7.89) | (8.29) | |
Research and Development Expense of Revenue |
19.93% | 20.88% | 18.72% | 21.42% | |
Selling, General and Administrative Expense of Revenue |
150.38% | 148.68% | 137.35% | 148.91% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
23.34% | 19.74% | 17.43% | 19.66% | |
Graham Net Nets |
0.13 | 0.10 | 0.20 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(38.52%) | (21.35%) | (28.87%) | (25.03%) | |
Free Cash Flow Yield |
(30.12%) | (16.11%) | (22.00%) | (18.46%) | |
Revenue per Share |
0.59 | 0.56 | 0.61 | 0.56 | |
Operating CF per Share |
(0.33) | (0.46) | (0.37) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.34) | (0.47) | (0.38) | (0.38) | |
Cash per Share |
2.44 | 2.74 | 2.90 | 3.25 | |
Shareholders Equity per Share |
0.75 | 1.10 | 1.51 | 1.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.75 | 1.10 | 1.51 | 1.84 | |
Free Cash Flow |
(8.94) | (12.29) | (9.83) | (10.00) | |
Working Capital |
78.36 | 87.26 | 88.33 | 96.67 | |
Capital Expenditures |
(0.11) | (0.12) | (0.07) | (0.29) | |
Net Current Asset Value |
17.16 | 26.13 | 36.18 | 44.62 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.28 | 9.06 | 9.97 | 8.62 | |
Average Payables |
3.45 | 2.87 | 3.21 | 3.45 | |
Average Inventory |
12.37 | 12.04 | 12.16 | 11.64 | |
Average Assets |
105.92 | 114.66 | 119.10 | 119.50 | |
Average Common Equity |
38.94 | 49.23 | 55.19 | 56.62 |
Columns are period end dates